ArticleMolecular psychiatry2010
Global proteomic profiling reveals altered proteomic signature in schizophrenia serum.
Article in Molecular psychiatry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The genetic landscape of neuro-related proteins in human plasma.Nature human behaviour · 2024Pooled it
- Systematic Review and Meta-Analysis of Mass Spectrometry Proteomics Applied to Human Peripheral Fluids to Assess Potential Biomarkers of Schizophrenia.International journal of molecular sciences · 2022Pooled it
- Peripheral Blood-Based Gene Expression Studies in Schizophrenia: A Systematic Review.Frontiers in genetics · 2021Pooled it
- Blood plasma proteomic biomarkers for forecasting transition to psychosis in an Asian cohort.Translational psychiatry · 2026Article
- A clinical prediction model for schizophrenia based on machine learning algorithms.Frontiers in medicine · 2025Article
- Evaluating Serum Proteome in Women with Obsessive-Compulsive Disorder/Bipolar Disorder Compared to Pure Obsessive- Compulsive Disorder Subjects and Healthy Controls.Iranian journal of child neurology · 2023Article
- Profiling the Skeletal Muscle Proteome in Patients on Atypical Antipsychotics and Mood Stabilizers.Brain sciences · 2022Article
- Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis.Molecular psychiatry · 2022Review
- Characterization of Potential Protein Biomarkers for Major Depressive Disorder Using Matrix-Assisted Laser Desorption Ionization/Time-of-Flight Mass Spectrometry.Molecules (Basel, Switzerland) · 2021Article
- Complement pathway changes at age 12 are associated with psychotic experiences at age 18 in a longitudinal population-based study: evidence for a role of stress.Molecular psychiatry · 2021Article
- Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence.JAMA psychiatry · 2021Article
- Emerging proteomic approaches to identify the underlying pathophysiology of neurodevelopmental and neurodegenerative disorders.Molecular autism · 2020Review
- The difference in serum proteomes in schizophrenia and bipolar disorder.BMC genomics · 2019Article
- Integrated Lipidomics and Proteomics Point to Early Blood-Based Changes in Childhood Preceding Later Development of Psychotic Experiences: Evidence From the Avon Longitudinal Study of Parents and Children.Biological psychiatry · 2019Article
- Multimodel inference for biomarker development: an application to schizophrenia.Translational psychiatry · 2019Article
- Proteomics in Schizophrenia: A Gateway to Discover Potential Biomarkers of Psychoneuroimmune Pathways.Frontiers in psychiatry · 2019Article
- Mass spectrometry identification of potential biomarker proteins in the 150-kD electrophoretic band in patients with schizophrenia.Medicine · 2018Article
- Proteomics for blood biomarker exploration of severe mental illness: pitfalls of the past and potential for the future.Translational psychiatry · 2018Review
- Blood-Based Protein Changes in Childhood Are Associated With Increased Risk for Later Psychotic Disorder: Evidence From a Nested Case-Control Study of the ALSPAC Longitudinal Birth Cohort.Schizophrenia bulletin · 2018Article
- Proteomics in the Diagnosis of Inborn Encephalopathies of Unknown Origin: A Myth or Reality.Advances in experimental medicine and biology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is one of the most severe psychiatric disorders affecting 1% of the world population. There is yet no empirical method to validate the diagnosis of the disease. The identification of an underlying molecular alteration could lead to an improved disease understanding and may yield an objective panel of biomarkers to aid in the diagnosis of this devastating disease. Presented is the largest reported liquid chromatography-mass spectrometry-based proteomic profiling study investigating serum samples taken from first-onset drug-naive patients compared with samples collected from healthy volunteers. The results of this large-scale study are presented along with enzyme-linked immunosorbent assay-based validation data.
Indexed as
Identifiers
19546861What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.